Table 2 Clinical characteristic between two groups

Basic clinical characteristics

Age (year)^a

61.0 (56.0, 67.0)

61.0 (53.0, 68.0)

Sex (M/F)

351/340

527/531

Comorbidities

 Hypertension (Y/N)

111/580

151/907

 COPD (Y/N)

71/620

97/961

 Diabetes mellitus (Y/N)

62/629

88/970

Smoking status (Y/N)

182/509

249/809

Pulmonary function

 FEV1 (L)^a

2.29 (1.71, 2.73)

2.28 (2.12, 2.44)

 FVC (L)^a

3.26 (2.72, 3.71)

3.20 (2.94, 3.48)

Surgical approach (n %)

 VATS

513 (74.2)

691 (65.3)

 Open

178 (25.8)

367 (34.7)

Amount of bleeding in operation^a

50.0 (20.0, 70.0)

180.0 (140.0, 220.0)

Surgery time^a

90.0 (70.0, 120.0)

120.0 (90.0, 150.0)

Postoperative LOS^a

4.0 (2.0,6.0)

6.0 (4.0, 9.0)

Total LOS^a

10.0 (7.0, 13.0)

13.0 (10.0, 16.0)

Pathological stage, (n %)

 Stage I

313 (45.3)

506 (47.8)

 Stage II

292 (42.3)

421 (39.8)

 Stage III

75 (10.9)

119 (11.2)

 Stage IV

11 (1.6)

12 (1.1)

Pathological type (n %)

 Adenocarcinoma

473 (68.5)

740 (69.9)

 Squamous cell carcinoma

192 (27.8)

281 (26.6)

 Other

26 (3.8)

37 (3.5)

In-hospital expense, ¥

 Total^a

46,047.7 (39,068.7, 52,733.8)

47,583.0 (43,761.6, 51,839.6)

 Material cost^a

23,742.6 (19,588.2, 27,844.8)

25,040.4 (21,439.5,29,871.5)

 Drug cost^a

7633.5 (5537.0, 10,100.3)

8157.6 (6453.2, 11,665.5)

Drainage volume^a

540.0 (275.0, 1170.5)

700.0 (150, 1710)

Duration of drainage^a

3.0 (2.0, 5.0)

5.0 (4.0, 7.0)